Evercore ISI added Cencora (COR) to the firm’s “Tactical Outperform” list as the firm updates estimates and makes several tactical calls in the Healthcare Technology & Distribution group ahead of Q3 earnings season. The firm keeps an Outperform rating and $340 price target on Cencora shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cencora’s Long-Term Potential Outweighs Near-Term Challenges: A Buy Rating Despite Conservative Growth Guidance
- Cencora Amends Credit Agreements for Enhanced Flexibility
- Cencora Settles Stockholder Derivative Action for $111.3M
- Cencora Appoints New Chairman Effective October 2025
- Cencora names Mark Durcan as Chairman of Its Board